Ongoing Medical Trials
Past Clinical Trials
Effects of the Thyroid Hormone Analog Triac on the Neurocognitive Phenotype in Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial I
Description: The current Trial (Triac Trial II) will investigate if Triac treatment in AHDS patients improves the neurocognitive phenotype.
Primary Purpose: Treatment
Estimated Study Start Date: June 2018
Estimated Study Completion Date: December 2022
Location: Erasmus Medical Center, Rotterdam
Principal Investigator: Dr. W.E. Wisser, Erasmus Medical Center
Recruitment Status: Now recruiting
Web page: https://clinicaltrials.gov/ct2/show/NCT0239645
Rescue of Infants With Mct8 Deficiency Under Emergency Use Single Patient Expanded Access Treatment
Description: MCT8 deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement.
Location: University of Miami, Miller School of Medicine, United States, Florida
Principal Investigator: Roy E Weiss, M.D.
Drug: Diiodothyropropionic acid (DITPA)
Web page: https://clinicaltrials.gov/ct2/show/NCT04143295
Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial.
Description:
The current trial will investigate if Triac treatment in AHDS patients:
1. reduces the toxic effects of the high T3 levels
2. restores the local TH deficiency in brain.
Primary Purpose: Treatment
Study Start Date: Oct 2014
Estimated completion date: May 2018
Location: Erasmus Medical Center, Rotterdam
Principal Investigator: Dr. W.E. Wisser, Erasmus Medical Center
Recruitment Status : Active, not recruiting
Web page: https://clinicaltrials.gov/ct2/show/NCT02060474